78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) – Pipeline Review, H2 2016’, provides in depth analysis on 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted pipeline therapeutics.

The report provides comprehensive information on the 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5)

The report reviews 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics and enlists all their major and minor projects

The report assesses 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Arno Therapeutics Inc

Intezyne Technologies Inc

Neonc Technologies Inc

Nuevolution AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) Overview 7

Therapeutics Development 8

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Products under Development by Stage of Development 8

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Products under Development by Therapy Area 9

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Products under Development by Indication 10

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Products under Development by Companies 14

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Products under Development by Universities/Institutes 17

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Companies Involved in Therapeutics Development 26

Arno Therapeutics Inc 26

Intezyne Technologies Inc 27

Neonc Technologies Inc 28

Nuevolution AB 29

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Drug Profiles 30

AR-12 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HA-15 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

IT-139 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

NEO-100 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Rasolvir - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Recombinant Peptide to Target TPI-1 and GRP-78 for Oncology - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule to Inhibit GRP78 for Oncology - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Dormant Projects 41

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Featured News & Press Releases 42

May 13, 2016: NeOnc Technologies Announces Initiation of Phase 1/2a Clinical Trial of NEO100 in Recurrent Glioblastoma Multiforme (GBM) 42

Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis 42

Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains 43

Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference 44

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 45

Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition 46

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 47

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 48

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 49

Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 49

May 24, 2012: Niiki Pharma To Present Final Phase I Clinical Data On Anti-Cancer Agent, NKP-1339 At Annual Meeting Of ASCO 2012 50

Feb 15, 2012: Niiki Pharma's New Compound Found To Be Promising Against Cancer 50

Feb 01, 2012: Niiki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339 51

Jan 17, 2012: Niiki Pharma Completes Phase I Dose Escalation For First-In-Man Anti-Cancer Agent, NKP-1339 52

Nov 15, 2011: Niiki Pharma Reports On Synergistic Activity Of New Anti-Cancer Agent NKP-1339 With Other Anti-Cancer Agents 53

Appendix 55

Methodology 55

Coverage 55

Secondary Research 55

Primary Research 55

Expert Panel Validation 55

Contact Us 55

Disclaimer 56

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

Pipeline by Arno Therapeutics Inc, H2 2016 26

Pipeline by Intezyne Technologies Inc, H2 2016 27

Pipeline by Neonc Technologies Inc, H2 2016 28

Pipeline by Nuevolution AB, H2 2016 29

Dormant Projects, H2 2016 41

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports